Payment overview · 2025
General Payments
$107.65
5 reported records · 5 companies
Healthcare provider profile · identity verified
Jennifer Smith, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · GRANBURY, TX · NPI 1952314767
Verified facts
What the public records show
CMS Open Payments records show Jennifer Smith, M.D. received $107.65 in general payments during 2025 across 5 reported records.
Lilly USA, LLC accounted for 22.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIBERZI as an associated drug or biological on 11354 records involving 5020 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Viberzi by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Mounjaro by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $23.67 | 22.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $23.47 | 21.8% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $22.07 | 20.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.36 | 18.0% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.08 | 17.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $107.65 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $23.67 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $23.47 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $22.07 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $19.36 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $19.08 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VIBERZI open payments reported associated product |
CMS Open Payments — General Payments 11354 supporting records · 5020 recipient NPIs · example record 1201352948 |
Viberzi · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 268 | 81 |
| Methylprednisolone | Methylprednisolone | 190 | 122 |
| Losartan Potassium | Losartan Potassium | 174 | 52 |
| Atorvastatin Calcium | Atorvastatin Calcium | 170 | 50 |
| Omeprazole | Omeprazole | 161 | 49 |
| Amlodipine Besylate | Amlodipine Besylate | 142 | 40 |
| Lisinopril | Lisinopril | 138 | 37 |
| Alprazolam | Alprazolam | 125 | 35 |
| Azithromycin | Azithromycin | 124 | 94 |
| Simvastatin | Simvastatin | 120 | 33 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 100 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 99 | 17 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 96 | 33 |
| Furosemide | Furosemide | 94 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 89 | 30 |
| Famotidine | Famotidine | 85 | 31 |
| Pantoprazole Sodium | Pantoprazole Sodium | 85 | 28 |
| Potassium Chloride | Potassium Chloride | 82 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 81 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 80 | 35 |
| Ozempic | Semaglutide | 76 | 12 |
| Fluconazole | Fluconazole | 72 | 49 |
| Montelukast Sodium | Montelukast Sodium | 72 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 68 | 30 |
| Estradiol | Estradiol | 68 | 20 |
| Gabapentin | Gabapentin | 68 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 67 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 66 | 19 |
| Metformin Hcl | Metformin Hcl | 66 | 23 |
| Sertraline Hcl | Sertraline Hcl | 62 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 61 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 59 | 17 |
| Glipizide Er | Glipizide | 56 | 15 |
| Temazepam | Temazepam | 53 | 13 |
| Clonazepam | Clonazepam | 52 | suppressed |
| Carvedilol | Carvedilol | 51 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 48 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 47 | 16 |
| Allopurinol | Allopurinol | 46 | 12 |
| Mounjaro | Tirzepatide | 43 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 43 | 12 |
| Tramadol Hcl | Tramadol Hcl | 42 | 14 |
| Trazodone Hcl | Trazodone Hcl | 40 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 38 | 33 |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | 13 |
| Atenolol | Atenolol | 35 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 35 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 35 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 33 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 31 | 18 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 31 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 25 |
| Synthroid | Levothyroxine Sodium | 29 | suppressed |
| Eliquis | Apixaban | 27 | suppressed |
| Prednisone | Prednisone | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Aripiprazole | Aripiprazole | 25 | suppressed |
| Meloxicam | Meloxicam | 25 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Mupirocin | Mupirocin | 23 | 17 |
| Lovastatin | Lovastatin | 22 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 21 | suppressed |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Pregabalin | Pregabalin | 20 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Lorazepam | Lorazepam | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Cephalexin | Cephalexin | 16 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Glimepiride | Glimepiride | 15 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 14 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 13 |
| Np Thyroid | Thyroid,pork | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Proctosol-Hc | Hydrocortisone | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Viberzi | Eluxadoline | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Primidone | Primidone | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $107.65 · 5 records | Lilly USA, LLC | MOUNJARO, The Cologuard Plus Collection Kit, VOQUEZNA, VRAYLAR, ZORYVE | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error